Fractyl
Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners.
Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science.
After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School.
This person is not in any offices
Fractyl
2 followers
Fractyl aims to bring curative therapies to the large populations of patients with metabolic disease. With their innovative products, their goal is to truly shift the treatment paradigm for patients with metabolic disease by focusing on their root cause in the intestine to provide meaningful, transformative, benefits to restore patient health from metabolic diseases.